Advanced Biosensors Integrating Electrochemistry, Optics, and Nanotechnology Revolutionize Early Cancer Detection

IEEE Access USA

Overview

This review highlights recent advancements in electrochemical, optical, and nanotechnology-based biosensors for early cancer detection, particularly for breast, prostate, and lung cancers. Cyclic voltammetry-based biosensors, for instance, achieve femtomolar detection limits and sub-10-minute response times, significantly outperforming traditional ELISA. Integration with microfluidics further enhances sensitivity and specificity, enabling predictive and multiplexed analysis. This convergence of technologies holds immense potential for improving diagnostic accuracy and facilitating earlier intervention for cancer patients.

In Depth

Background

Cancer remains a leading cause of death worldwide, and early detection is directly linked to improved treatment outcomes and patient survival rates. However, existing cancer diagnostic methods often face challenges such as invasiveness, high cost, time constraints, and low sensitivity in early stages. To overcome these hurdles, the development of non-invasive, rapid, and highly sensitive biosensor technologies has become a central focus of recent research. Specifically, hybrid approaches combining different principles like electrochemistry, optics, and nanotechnology are highly anticipated as next-generation cancer diagnostic tools.

Key Findings / Results

This review article provides a detailed analysis of cutting-edge biosensor technologies for early cancer detection. Key advancements include:

• Electrochemical Biosensors: These sensors demonstrate high sensitivity and selectivity in detecting cancer biomarkers (e.g., proteins, nucleic acids, metabolites). Notably, cyclic voltammetry (CV)-based biosensors offer detection limits down to the femtomolar (fM) scale and rapid response times of less than 10 minutes, a significant improvement over traditional Enzyme-Linked Immunosorbent Assay (ELISA), which can take several hours. This implies a dramatic reduction in diagnostic turnaround time.
• Optical Biosensors: Utilizing principles such as surface plasmon resonance (SPR), fluorescence, and chemiluminescence, these biosensors enable label-free biomarker detection. They excel in high sensitivity and multiplexing capabilities, contributing to the identification of trace biomarkers in complex biological samples.
• Integration of Nanotechnology: Nanomaterials like gold nanoparticles, quantum dots, carbon nanotubes, and graphene enhance sensor performance by increasing surface area and providing signal amplification, leading to a dramatic increase in detection sensitivity. These materials are also suitable for immobilizing biorecognition elements (e.g., antibodies, aptamers), further improving specificity.
• Fusion with Microfluidic Technology: Integration with microfluidic devices (lab-on-a-chip) enhances automation of sample processing, reduces reagent consumption, and improves multiplexing capabilities. This allows for the simultaneous and highly efficient detection of multiple cancer biomarkers from minute sample volumes.

These technologies have been applied and validated for detecting specific biomarkers of breast, prostate, and lung cancers (e.g., PSA, HER2, circulating tumor cells).

Technical Significance & Outlook

Biosensors integrating electrochemistry, optics, and nanotechnology hold the potential to revolutionize early cancer diagnostics. Their rapid and highly sensitive detection capabilities can reduce patient anxiety and expand opportunities for early therapeutic intervention. Particularly, the realization of point-of-care (POCT) devices would enable accessible cancer screening and diagnosis in remote areas or regions with limited medical resources, contributing to global health equity. Furthermore, multiplex analysis through microfluidic integration allows for the analysis of “biomarker panels”—combinations of multiple biomarkers—rather than just single markers, thereby increasing diagnostic reliability and predictive accuracy. In the future, these biosensors are expected to be incorporated into routine health check-ups, becoming a crucial pillar of personalized preventive medicine.